Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NYSE:ENOV NASDAQ:LMAT NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.00-2.2%$12.43$11.68▼$25.36$554.65M1.12384,984 shs142,392 shsENOVEnovis$34.33-4.5%$33.00$28.83▼$49.83$1.96B1.7898,219 shs356,844 shsLMATLeMaitre Vascular$83.89-2.2%$82.62$71.42▼$109.58$1.89B0.82169,565 shs31,552 shsNVCRNovoCure$17.70-4.1%$17.67$14.17▼$34.13$1.98B0.721.13 million shs261,804 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL-0.16%-0.81%-4.80%-1.76%-36.82%ENOVEnovis+1.24%+6.81%+7.16%+12.57%-17.93%LMATLeMaitre Vascular+1.42%+1.59%+2.53%+3.54%+2.78%NVCRNovoCure+1.48%+4.26%+0.44%+11.88%+9.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICAL1.9082 of 5 stars0.03.00.00.01.31.72.5ENOVEnovis3.5898 of 5 stars3.43.00.00.03.21.71.9LMATLeMaitre Vascular2.5891 of 5 stars2.21.03.30.02.12.51.3NVCRNovoCure3.6031 of 5 stars3.41.00.04.51.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/AENOVEnovis 2.80Moderate Buy$55.6061.96% UpsideLMATLeMaitre Vascular 2.33Hold$97.8316.62% UpsideNVCRNovoCure 2.71Moderate Buy$32.4383.20% UpsideCurrent Analyst Ratings BreakdownLatest AVNS, NVCR, ENOV, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.81$11.53 per share1.04$18.03 per share0.67ENOVEnovis$2.11B0.93$18.56 per share1.85$45.10 per share0.76LMATLeMaitre Vascular$226.26M8.38$2.37 per share35.40$15.00 per share5.59NVCRNovoCure$605.22M3.26N/AN/A$3.33 per share5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.37N/A6.93N/A-55.80%6.26%4.63%7/30/2025 (Estimated)ENOVEnovis-$825.49M-$13.95N/A10.76N/A-37.65%5.99%3.44%8/6/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9842.1938.662.2319.96%13.53%9.78%8/5/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)Latest AVNS, NVCR, ENOV, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ENOVEnovis$0.74N/AN/AN/A$555.80 millionN/A8/5/2025Q2 2025LMATLeMaitre Vascular$0.57N/AN/AN/A$62.48 millionN/A7/30/2025Q2 2025AVNSAVANOS MEDICAL$0.18N/AN/AN/A$165.50 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.95%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest AVNS, NVCR, ENOV, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56ENOVEnovis0.522.551.32LMATLeMaitre Vascular0.4816.4913.83NVCRNovoCure0.271.471.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ENOVEnovis98.45%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ENOVEnovis2.70%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableAVNS, NVCR, ENOV, and LMAT HeadlinesRecent News About These CompaniesNovoCure (NASDAQ:NVCR) Research Coverage Started at LADENBURG THALM/SH SHJuly 11 at 2:11 AM | americanbankingnews.comLadenburg Thalmann Initiates Coverage of NovoCure (NVCR) with Buy RecommendationJuly 9 at 3:55 AM | msn.comNovoCure (NASDAQ:NVCR) Coverage Initiated at LADENBURG THALM/SH SHJuly 8 at 8:40 AM | marketbeat.comSummit Trail Advisors LLC Acquires 40,570 Shares of NovoCure Limited (NASDAQ:NVCR)July 2, 2025 | marketbeat.comBrokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83July 2, 2025 | americanbankingnews.comStrong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year lossJune 30, 2025 | finance.yahoo.comNovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?June 30, 2025 | zacks.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Taylor Frigon Capital Management LLCJune 30, 2025 | marketbeat.comNovocure to Report Second Quarter 2025 Financial ResultsJune 30, 2025 | businesswire.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsJune 29, 2025 | marketbeat.comDemystifying NovoCure: Insights From 4 Analyst ReviewsJune 27, 2025 | benzinga.comNovoCure's (NVCR) "Overweight" Rating Reiterated at Piper SandlerJune 27, 2025 | marketbeat.comSG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)June 23, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?June 18, 2025 | marketbeat.comWhat Makes NovoCure (NVCR) a New Buy StockJune 18, 2025 | zacks.comGAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)June 17, 2025 | marketbeat.comSimon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)June 16, 2025 | marketbeat.comNVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialJune 6, 2025 | zacks.comResults From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingJune 2, 2025 | businesswire.comNovocure data support pancreatic cancer approval, says Wells FargoJune 2, 2025 | msn.comNovocure study shows improved pancreatic cancer survivalJune 2, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseEnovix Shares Hit 6-Month High; Long-Term Highs to FollowBy Thomas Hughes | July 10, 2025View Enovix Shares Hit 6-Month High; Long-Term Highs to FollowAVNS, NVCR, ENOV, and LMAT Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.00 -0.27 (-2.16%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Enovis NYSE:ENOV$34.33 -1.61 (-4.48%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$83.89 -1.86 (-2.17%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$17.70 -0.76 (-4.11%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
